LivaNova(US:LIVN)2026-02-25 14:02Financial Data and Key Metrics Changes - In Q4 2025, revenue was $361 million, a 9.5% increase on a constant currency and organic basis compared to the prior year [22] - Adjusted diluted earnings per share rose to $0.86 from $0.81 in Q4 2024, reflecting strong revenue growth and effective cost management [24] - Cash balance increased to $636 million from $429 million at year-end 2024, driven by improved operating cash flows [26] - Total debt decreased to $377 million from $628 million at year-end 2024 due to early repayments [26] Business Line Data and Key Metrics Changes - Cardiopulmonary segment revenue was $207 million in Q4 2025, a 10% increase year-over-year, with full-year revenue growing 13% [8] - Epilepsy segment revenue increased by 9% in Q4 2025, with full-year growth of 6%, supported by strong commercial execution globally [10][11] Market Data and Key Metrics Changes - U.S. Epilepsy revenue grew 8% year-over-year, while Europe and Rest of World regions combined saw a 17% increase [10] - The heart-lung machine (HLM) revenue grew in the mid-single digits in Q4 2025, with full-year revenue growth in the mid-teens [8] Company Strategy and Development Direction - The company aims to transform into a best-in-class med tech company, focusing on high-growth markets like obstructive sleep apnea (OSA) and leveraging competitive advantages [6][7] - Investments in innovation, digital platforms, and leadership upgrades are being prioritized to support strategic execution [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver sustained value for shareholders, highlighting the durability of core businesses and the potential for growth in new markets [32][34] - The company anticipates revenue growth of 6% to 7% for 2026, consistent with the 2025-2028 framework [28][31] Other Important Information - The company received FDA approval for its cloud-based digital health platform, which will enhance connected care in epilepsy [15] - The reimbursement for VNS Therapy procedures under Medicare increased significantly, which is expected to improve hospital economics and patient access [12] Q&A Session Summary Question: Insights on cardiopulmonary growth guidance for FY 2026 - Management expects continued growth drivers from Essenz upgrades, market share gains, and pricing strategies, with a moderation in price premium for Essenz [36][37] Question: Clarification on epilepsy business guidance - Management noted significant tailwinds from improved reimbursement and clinical evidence, which are expected to support growth in the epilepsy business [42][43] Question: Impact of reimbursement changes on VNS business - Management indicated that they have not seen any denials in the cohorts tracked, and the reimbursement changes are expected to support penetration of new patient implants [50] Question: Specifics on tender timing and geographic impact - Management confirmed that the shift in placements was immaterial and will be fully captured in Q1 2026, with optimism about the launch in China [52][53] Question: Updates on Medicaid reimbursement changes - Management stated that Medicaid is expected to follow Medicare reimbursement levels, although it may take time to work through state-level adjustments [82]